- Home
- KPRX vs NUAI Comparison
KPRX vs NUAI Comparison
Compare KPRX & NUAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- NUAI
- Stock Information
- Founded
- KPRX 1998
- NUAI N/A
- Country
- KPRX United States
- NUAI United States
- Employees
- KPRX N/A
- NUAI N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NUAI Oil & Gas Production
- Sector
- KPRX Health Care
- NUAI Energy
- Exchange
- KPRX Nasdaq
- NUAI Nasdaq
- Market Cap
- KPRX 9.2M
- NUAI 10.4M
- IPO Year
- KPRX N/A
- NUAI N/A
- Fundamental
- Price
- KPRX $2.65
- NUAI $0.47
- Analyst Decision
- KPRX Strong Buy
- NUAI
- Analyst Count
- KPRX 1
- NUAI 0
- Target Price
- KPRX $10.00
- NUAI N/A
- AVG Volume (30 Days)
- KPRX 32.4K
- NUAI 7.3M
- Earning Date
- KPRX 11-07-2025
- NUAI 11-14-2025
- Dividend Yield
- KPRX N/A
- NUAI N/A
- EPS Growth
- KPRX N/A
- NUAI N/A
- EPS
- KPRX N/A
- NUAI N/A
- Revenue
- KPRX N/A
- NUAI $718,761.00
- Revenue This Year
- KPRX N/A
- NUAI N/A
- Revenue Next Year
- KPRX N/A
- NUAI N/A
- P/E Ratio
- KPRX N/A
- NUAI N/A
- Revenue Growth
- KPRX N/A
- NUAI 14.80
- 52 Week Low
- KPRX $2.25
- NUAI $0.32
- 52 Week High
- KPRX $4.18
- NUAI $12.29
- Technical
- Relative Strength Index (RSI)
- KPRX 46.53
- NUAI N/A
- Support Level
- KPRX $2.60
- NUAI N/A
- Resistance Level
- KPRX $2.80
- NUAI N/A
- Average True Range (ATR)
- KPRX 0.11
- NUAI 0.00
- MACD
- KPRX -0.01
- NUAI 0.00
- Stochastic Oscillator
- KPRX 21.21
- NUAI 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About NUAI New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.